The Conversation (0)
More Featured Articles and Inverviews
Imara Inc is a clinical-stage biopharmaceutical company engaged in developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Its lead product candidate, tovinontrine (IMR-687), is an oral, highly selective, potent small-molecule inhibitor of phosphodiesterase-9, or PDE9.
Latest News
Latest News
Outlook Reports world
Browse Companies
MARKETS
COMMODITIES
CURRENCIES
Alert Options
No alert set
INN Article Notification
Alert Option
You will be notified when this event occurs. No additional settings needed.